EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies



A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies



Blood 109(6): 2571-2578



Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzyme target of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV(+) lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV(+) lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV(+) lymphoid malignancies which are refractory to other regimens.

(PDF emailed within 0-6 h: $19.90)

Accession: 013226024

Download citation: RISBibTeXText

PMID: 17119113

DOI: 10.1182/blood-2006-01-024703



Related references

Phase I/II trial of Arginine Butyrate and ganciclovir in Epstein-Barr virus-associated lymphoid malignancies. Journal of Clinical Oncology 24(18_suppl): 7542-7542, 2016

Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells, Molecules & Diseases 24(2): 114-123, 1998

Arginine butyrate-induced susceptibility to ganciclovir in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 411-412, 1996

Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting (41): 544, March, 2000

Treatment of Epstein-Barr virus -associated lymphomas and PTLD using Arginine Butyrate to induce viral TK gene expression Initial findings of a phase I/II trial. Blood 94(10 SUPPL 1 PART 1): 523a, Nov 15, 1999

Epstein barr virus lymphoid cell interactions 2. the influence of epstein barr virus replication cycle on natural killing and antibody dependent cellular cyto toxicity against epstein barr virus infected cells. Clinical and Experimental Immunology 48(3): 589-601, 1982

Circulating cell-free Epstein-Barr virus DNA levels in patients with EBV-associated lymphoid malignancies. Annals of the New York Academy of Sciences 945: 80-83, 2001

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81(6): 856-861, 2006

Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. British Journal of Haematology 111(1): 239-246, 2000

The role of Epstein-Barr virus in lymphoid malignancies. Critical Reviews in Oncology/Hematology 26(1): 25-41, 1997

Studies of epstein barr virus lymphoid cell interactions in two patients with the x linked lymphoproliferative syndrome normal epstein barr specific hla restricted cytotoxicity. Clinical & Experimental Immunology 63(2): 280-289, 1986

Induction of epstein barr virus dna demethylation and of epstein barr virus specific transcription in daudi cells treated with 12 o tetradecanoylphorbol 13 acetate and n butyrate. Intervirology 22(4): 201-210, 1984

Studies on the induction of epstein barr virus dna polymerase and dnase by the combined action of 12 o tetradecanoylphorbol 13 acetate and n butyrate in epstein barr virus carrying cells. Federation Proceedings 45(4): 1090, 1986

Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infectious Disease 3(3): 177-185, 2001